Charles M. Rudin

发表

R. Deberardinis, T. Oliver, Yang Xie, 2024, bioRxiv.

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.

A. Drilon, M. Kris, S. Chandarlapaty, 2024, European journal of cancer.

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

A. Tsirigos, M. Hayashi, J. Poirier, 2024, Science advances.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

M. Krasnow, J. Minna, P. Massion, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.

Jason S. Lewis, H. Schoder, N. Rekhtman, 2024, The Lancet. Oncology.

Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions

Joseph B Hiatt, C. Dive, R. Santana-Davila, 2024, Science advances.